<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T08:39:50Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/112018" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/112018</identifier><datestamp>2026-05-15T19:46:49Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Nguyen, Thi Thuy Tien</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair">Cerione, Richard A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Baird, Barbara A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Crane, Brian</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-10-31T16:20:28Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-10-31T16:20:28Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022-08</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 13195</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 29319973</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/112018</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/bd08-g687</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">15578829</dim:field>
   <dim:field mdschema="dc" element="description">152 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Metabolic reprogramming has been established as a major hallmark for cancer progression. Many cancer cells become dependent on glutamine catabolism, which thus has gained a great deal of attention for being a potentially important therapeutic target. The mitochondrial glutaminase enzymes are upregulated in many cancer cells to catalyze the hydrolysis of glutamine to glutamate, initiating glutamine catabolism. Therefore, mechanistic understanding of the regulation of these enzymes has important implications for the development of strategies to inhibit malignant growth. Here in my thesis, I will first present a novel mechanism for the activation of glutaminase C (GAC), an isoform implicated in the progression of many aggressive cancers. GAC acquires maximal catalytic activity upon binding to anionic activators such as inorganicphosphate. Using a combination of biophysical approaches, I showed that in the absence of phosphate, glutamine binding to the GAC tetramer exhibits positive cooperativity. This cooperativity is coupled to the transition between the open and closed conformation of the ‘lid’, a tyrosine residue located at the edge of the catalytic site, which controls substrate access to this site. Phosphate allows glutamine to independently bind with high affinity to all subunits, which then undergo simultaneous catalysis with all the lids in a uniform conformation. This mechanism shows how the regulated transitioning between different conformational states of GAC ensures the maximal catalytic activity of the enzyme is acquired in cancer cells only when an allosteric activator is available. Secondly, I will discuss the underlying basis for the differences in potencies exhibited by members of the BPTES/CB-839 class of inhibitors, which selectively target GAC. The mechanism of inhibition remained poorly understood as the differences in potency could not be explained with standard cryo-cooled X-ray crystal structures of GAC bound to these compounds. However, using an emerging technique, serial room temperature crystallography, I showed that clear differences were observed between the binding conformations of inhibitors with significantly different potencies. The results were further corroborated using recently established fluorescence assays that directly read-out inhibitor binding to GAC. Collectively, these findings have highlighted novel strategies for designing more potent GAC inhibitors as potential cancer therapeutics.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="rights">Attribution 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri">https://creativecommons.org/licenses/by/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject">anti-cancer drugs</dim:field>
   <dim:field mdschema="dc" element="subject">cancer</dim:field>
   <dim:field mdschema="dc" element="subject">crystallography</dim:field>
   <dim:field mdschema="dc" element="subject">glutaminase</dim:field>
   <dim:field mdschema="dc" element="subject">structure‐function</dim:field>
   <dim:field mdschema="dc" element="subject">Warburg effects</dim:field>
   <dim:field mdschema="dc" element="title">THE ALLOSTERIC REGULATION OF GLUTAMINASE ENZYMES: DRIVING GLUTAMINE CATABOLISM IN CANCER CELLS</dim:field>
   <dim:field mdschema="dc" element="type">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/15578829</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemistry and Chemical Biology</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Chemistry and Chemical Biology</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Nguyen, Thi Thuy Tien</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="27e0338f-f66a-4f1e-8b15-28188649deb5">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>THE ALLOSTERIC REGULATION OF GLUTAMINASE ENZYMES: DRIVING GLUTAMINE CATABOLISM IN CANCER CELLS&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2022-08&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/bd08-g687&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Nguyen, Thi Thuy Tien&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by/4.0/&lt;/License>
    &lt;Keyword>anti-cancer drugs&lt;/Keyword>
    &lt;Keyword>cancer&lt;/Keyword>
    &lt;Keyword>crystallography&lt;/Keyword>
    &lt;Keyword>glutaminase&lt;/Keyword>
    &lt;Keyword>structure‐function&lt;/Keyword>
    &lt;Keyword>Warburg effects&lt;/Keyword>
   	&lt;Abstract>Metabolic reprogramming has been established as a major hallmark for cancer progression. Many cancer cells become dependent on glutamine catabolism, which thus has gained a great deal of attention for being a potentially important therapeutic target. The mitochondrial glutaminase enzymes are upregulated in many cancer cells to catalyze the hydrolysis of glutamine to glutamate, initiating glutamine catabolism. Therefore, mechanistic understanding of the regulation of these enzymes has important implications for the development of strategies to inhibit malignant growth. Here in my thesis, I will first present a novel mechanism for the activation of glutaminase C (GAC), an isoform implicated in the progression of many aggressive cancers. GAC acquires maximal catalytic activity upon binding to anionic activators such as inorganicphosphate. Using a combination of biophysical approaches, I showed that in the absence of phosphate, glutamine binding to the GAC tetramer exhibits positive cooperativity. This cooperativity is coupled to the transition between the open and closed conformation of the ‘lid’, a tyrosine residue located at the edge of the catalytic site, which controls substrate access to this site. Phosphate allows glutamine to independently bind with high affinity to all subunits, which then undergo simultaneous catalysis with all the lids in a uniform conformation. This mechanism shows how the regulated transitioning between different conformational states of GAC ensures the maximal catalytic activity of the enzyme is acquired in cancer cells only when an allosteric activator is available. Secondly, I will discuss the underlying basis for the differences in potencies exhibited by members of the BPTES/CB-839 class of inhibitors, which selectively target GAC. The mechanism of inhibition remained poorly understood as the differences in potency could not be explained with standard cryo-cooled X-ray crystal structures of GAC bound to these compounds. However, using an emerging technique, serial room temperature crystallography, I showed that clear differences were observed between the binding conformations of inhibitors with significantly different potencies. The results were further corroborated using recently established fluorescence assays that directly read-out inhibitor binding to GAC. Collectively, these findings have highlighted novel strategies for designing more potent GAC inhibitors as potential cancer therapeutics.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>